Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine [0.03%]
用于开发mRNA疫苗的黑色素瘤肿瘤抗原和免疫亚型分析
Haiqin Ping,Wenjun Yu,Xiaoming Gong et al.
Haiqin Ping et al.
Melanoma has a high degree of malignancy and mortality. While there are some hopeful clinical trials for melanoma treatment in progress, they have not yet to yield significant long-term cure rates. Cancer vaccines including mRNA are current...
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors [0.03%]
卢比卡丁联合每周一次紫杉醇单药或联合贝伐珠单抗治疗晚期实体瘤的Ⅰ期临床研究
Emiliano Calvo,Cristiana Sessa,Guilherme Harada et al.
Emiliano Calvo et al.
Lurbinectedin and paclitaxel showed synergism in preclinical studies and have non-completely overlapping toxicity profiles. This phase I trial evaluated a combination of paclitaxel and lurbinectedin with/without bevacizumab in advanced tumo...
Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR [0.03%]
酮酚丁胺通过促进miR-27b-3p和EGFR高表达促进小鼠乳腺肿瘤生长
Li-Kuei Chen,Chien-Hung Shih,Shiou-Sheng Chen et al.
Li-Kuei Chen et al.
Non-medical use of ketamine as an adulterant to ecstasy is more prevalent than amphetamine in Taiwan. Ketamine's effect on immunosuppression might play some functional role in tumor growth, while it is still controversial whether ketamine a...
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors [0.03%]
一项Ⅰ期研究：评估利福平对rifampin患者药代动力学的影响：一种NEDD8激活剂抑制剂在实体瘤患者中的应用
Xiaofei Zhou,Ulka Vaishampayan,Devalingam Mahalingam et al.
Xiaofei Zhou et al.
Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase 1...
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors [0.03%]
Envafolimab（KN035）治疗晚期实体瘤的Ⅰ期临床研究
Toshio Shimizu,Takako Eguchi Nakajima,Noboru Yamamoto et al.
Toshio Shimizu et al.
Envafolimab is the first and only globally approved subcutaneously injectable PD-L1 antibody. This open-label, multicenter Phase 1 trial assessed the safety, tolerability, pharmacokinetic (PK) profile, and efficacy of envafolimab as a singl...
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors [0.03%]
一项开放标签、交叉设计的研究：比较不同剂型并评估食物对pimitespib药代动力学影响的临床研究
Yoshito Komatsu,Tsuneo Shimokawa,Kohei Akiyoshi et al.
Yoshito Komatsu et al.
This study compared the bioavailability of two pimitespib formulations (Formulations A and B), evaluated the food effect on Formulation A, and evaluated the safety and efficacy of multiple pimitespib doses in patients with solid tumors. Thi...
Multicenter Study
Investigational new drugs. 2022 Oct;40(5):1011-1020. DOI:10.1007/s10637-022-01285-9 2022
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study [0.03%]
吉西他滨联合白蛋白结合型紫杉醇治疗晚期胰腺癌老年患者的疗效和安全性：一项单中心回顾性队列研究
Sae Ohwada,Akiko Todaka,Hiroshi Nakase et al.
Sae Ohwada et al.
Purpose: This study aimed to evaluate the effectiveness and safety of gemcitabine (GEM) plus nab-paclitaxel (GnP) in patients aged ≥ 75 years with advanced pancreatic cancer and compare it with monotherapy (GEM or S-1). ...
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome [0.03%]
达沙替尼诱导的肾病综合征的临床特征、诊断和处理措施
Yang He,Weijin Fang,Zuojun Li et al.
Yang He et al.
Knowledge of dasatinib-induced nephrotic syndrome is largely based on case reports. The clinical features of dasatinib-induced nephrotic syndrome are unknown. We collected case reports of 25 patients with nephrotic syndrome and analyzed the...
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells [0.03%]
单臂PEG修饰的来自热稳定芽孢杆菌天青素色芽球菌的变异鼠胃癌蛋白酶（BCA-M-PEG20）能诱导胃癌细胞凋亡、自噬，引起细胞周期阻滞并抑制其生长
Sai-Fung Chung,Suet-Ying Tam,Chi-Fai Kim et al.
Sai-Fung Chung et al.
Gastric cancer is one of the most common malignant solid tumors in the world, especially in Asia with high mortality due to a lack of effective treatment. The potential usage of the newly constructed arginine-depleting enzyme-mono-PEGylated...
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport [0.03%]
曲米扎平(一种四环抗抑郁药)的抗肿瘤活性主要通过抑制SLC1A5介导的谷氨酰胺转运实现
Zelin Duan,Zhiyun Zhou,Feifei Lu et al.
Zelin Duan et al.
Targeting tumor metabolic vulnerabilities such as "glutamine addiction" has become an attractive approach for the discovery of novel antitumor agents. Among various mechanisms explored, SLC1A5, a membrane transporter that plays an important...